Navigation Links
Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
Date:11/13/2008

STOCKHOLM, November 13 /PRNewswire/ -- Karolinska Development AB, a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science announced today the appointment of Dr. Carl Harald Janson as investment manager.

"Carl Harald is an outstanding addition to our management team," stated Conny Bogentoft, Chief Executive Officer of Karolinska Development. "His extensive experience within the medical, pharmaceutical and investment arenas will provide an invaluable perspective for our future growth". His former activities have included work as Medical Adviser for Clinical Research and Director of Immunology for Preclinical R&D at Astra Arcus AB, Senior Financial Analyst at Hagstromer & Qviberg Fondkommission AB and Danske Securities, Danske Bank in Stockholm. He moved into fund management with companies including Carnegie Investment Bank AB.

He is a Medical Doctor holding a PhD. from Karolinska Institutet in Stockholm and qualified as a Certified European Financial Analyst at Stockholm School of Economics.

Carl Harald will take responsibility for the Karolinska Development pharma project portfolio. Bringing with him a vast network of individuals with both management and operational skills, which will further strengthen the cost effective business model used by Karolinska Development.

About Karolinska Development

Karolinska Development is a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science innovations. Professionals in business development and management, supported by a network of experienced technical specialists, ensure fast and efficient development. This enables Karolinska Development to rapidly build value in high risk opportunities, through long term lead investor position from seed stage; developing the medical products of the future.

Karolinska Development's office is located at the Karolinska Institute Science Park, Sweden http://www.karolinskadevelopment.com
More about Karolinska Development: http://www.karolinskadevelopment.com

Contact: Conny Bogentoft, CEO

Tel: +46(0)8-524861-43

e-mail: info@karolinskadevelopment.com


'/>"/>
SOURCE Karolinska Development AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
5. Global Experts Explore Entire Spectrum of Aids Vaccine Development
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. SemBioSys updates Apo AI development program
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... compared the implantation and pregnancy rates in frozen and fresh in vitro ... of progesterone and maternal age to IVF success. , After comparing the results ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
Breaking Biology Technology:
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):